Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

September 2021

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 SEPTEMBER 2021

- Bezafibrate tab 200 mg (Bezalip) and tab long-acting 400 mg (Bezalip Retard) – price increase and addition of PSS
- Bromocriptine tab 2.5 mg – to be delisted 1 March 2022
- Cabergoline (Dostinex) tab 0.5 mg – amended restriction criteria
- Citalopram hydrobromide (PSM Citalopram) tab 20 mg – price increase and addition of PSS
- Clarithromycin (Klacid) tab 250 mg and 500 mg – new listing and addition HSS
- Clarithromycin (Apo-Clarithromycin) tab 250 mg and 500 mg – to be delisted 1 February 2022
- Clomipramine hydrochloride (Clomipramine Teva) tab 10 mg and 25 mg – new listing and addition of HSS
- Clomipramine hydrochloride (Apo-Clomipramine) tab 10 mg and 25 mg – to be delisted 1 February 2022
- Diclofenac sodium (Voltaren SR) tab long-acting 75 mg – new listing
- Diclofenac sodium (Apo-Diclo SR) tab long-acting 75 mg – to be delisted 1 May 2022
- Domperidone (Pharmacy Health) tab 10 mg – price increase and addition of PSS
- Dulaglutide (Trulicity) inj 1.5 mg per 0.5 ml prefilled pen – new listing, restriction criteria and not to be given in combination with a funded SGLT-2 inhibitor
- Empagliflozin (Jardiance) tab 10 mg and 25 mg – amended restriction criteria and not to be given in combination with a funded GLP-1 agonist
- Empagliflozin with metformin hydrochloride (Jardiamet) tab 5 mg with 1,000 mg metformin hydrochloride, tab 5 mg with 500 mg metformin hydrochloride, tab 12.5 mg with 1,000 mg metformin hydrochloride and tab 12.5 mg with 500 mg metformin hydrochloride – amended restriction criteria and not to be given in combination with a funded GLP-1 agonist
- Flumazenil (Hameln) inj 0.1 mg per ml, 5 ml ampoule – price decrease and addition of PSS
- Fluorouracil (Fluorouracil Accord) inj 50 mg per ml, 20 ml vial and 100 ml vial – new listing and addition of PSS
- Fluorouracil (Fluorouracil Ebewe) inj 50 mg per ml, 20 ml vial and 100 ml vial – to be delisted 1 February 2022
- Gabapentin (Nupentin) cap 100 mg, 300 mg and 400 mg – new listing and addition of HSS

Summary of decisions – effective 1 September 2021 (continued)

- Gabapentin (Apo-Gabapentin) cap 100 mg, 300 mg and 400 mg – to be delisted 1 February 2022 and HSS expired 1 September 2021
- Hydrocortisone butyrate (Locoid Lipocream) crm 0.1%, 100 g – price decrease
- Icatibant (Firazyr) inj 10 mg per ml, 3 ml prefilled syringe – new Pharmacode (2617560) listing
- Icatibant (Firazyr) inj 10 mg per ml, 3 ml prefilled syringe – Pharmacode (2440180) to be delisted 1 March 2022
- Ketamine (Ketamine-Baxter) inj 100 mg per ml, 2 ml ampoule – price decrease and delisting delayed to 1 January 2022
- Latanoprost (Teva) eye drops 0.005%, 2.5 ml – price increase and addition of PSS
- Lidocaine [lignocaine] hydrochloride with adrenaline inj 2% with adrenaline 1:100,000, 1.7 ml dental cartridge – new listing
- Lopinavir with ritonavir (Lopinavir/Ritonavir Mylan) tab 100 mg with ritonavir 25 mg and tab 200 mg with ritonavir 50 mg – new listing and addition of PSS
- Lopinavir with ritonavir (Kaletra) tab 100 mg with ritonavir 25 mg and tab 200 mg with ritonavir 50 mg – to be delisted 1 February 2022
- Macrogol 3350 with ascorbic acid, potassium chloride, sodium chloride and citric acid with magnesium oxide, sodium picosulfate (e.g. Prepkit-C) powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet (2) – new listing
- Mometasone furoate crm 0.1% 15 g and 50 g (Elocon Alcohol Free) and oint 0.1% 15 g (Elocon) – price increase and addition PSS
- Mometasone furoate (Elocon) oint 0.1%, 50 g – addition PSS
- Mometasone furoate (Elocon) lotn 0.1%, 30 ml – price decrease and addition PSS
- Octreotide (Octreotide Depot Teva) inj depot 10 mg, 20 mg and 30 mg prefilled syringe - presentation description change, new listing, addition of PSS and amended restriction criteria
- Octreotide (Sandostain LAR) inj depot 10 mg, 20 mg and 30 mg prefilled syringe – to be delisted 1 March 2022
- Oxybutynin (Apo-Oxybutynin) oral liq 5 mg per 5 ml, 473 ml – to be delisted 1 May 2022
- Quinapril tab 5 mg (Arrow-Quinapril 5) – price decrease and addition of PSS
- Quinapril tab 10 mg (Arrow-Quinapril 10) and tab 20 mg (Arrow-Quinapril 20) – price increase and addition of PSS

Summary of decisions – effective 1 September 2021 (continued)

- Rivastigmine patch 4.6 mg per 24 hour (Rivastigmine Patch BNM 5) and patch 9.5 mg per 24 hour (Rivastigmine Patch BNM 10) – new listing and addition of PSS
- Rivastigmine (Generic Partners) patch 4.6 mg per 24 hour and 9.5 mg per 24 hour – to be delisted 1 February 2022
- Sodium hyaluronate [hyaluronic acid] (Healon GV Pro) inj 18 mg per ml, 0.85 ml syringe – new listing and transfer of HSS
- Sodium hyaluronate [hyaluronic acid] (Healon GV) inj 14 mg per ml, 0.55 ml syringe – to be delisted 1 January 2022 and HSS to be expired on 31 August 2021
- Sodium hyaluronate [hyaluronic acid] (Hylo-Fresh) eye drops 1 mg per ml, 10 ml – delisting brought forward to 1 September 2021
- Sumatriptan (Sumagran) tab 50 mg and 100 mg – new listing and addition of HSS
- Sumatriptan (Apo-Sumatriptan) tab 50 mg and 100 mg – to be delisted 1 February 2022 and HSS to be expired 31 August 2021
- Taurine cap 500 mg – new listing
- Thymol glycerin (PSM) compound, BPC – to be delisted 1 February 2022

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 September 2021

ALIMENTARY TRACT AND METABOLISM

11 SGLT2 Inhibitors (amended restriction criteria)

Restricted
Initiation
Any of the following:
1. For continuation use; or
2. Patient has previously had an initial approval for a GLP-1 agonist; or
3. All of the following;
   3.1. Patient has type 2 diabetes; and
   3.2. Any of the following:
      3.2.1. Patient is Māori or any Pacific ethnicity*; or
      3.2.2. Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
      3.2.3. Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
      3.2.4. Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
      3.2.5. Patient has diabetic kidney disease (see note b)*; and
   3.3. Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months~~; and~~
   ~~3.4. Treatment will not be used in combination with a funded GLP-1 agonist.~~

Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m^2 in the presence of diabetes, without alternative cause.

12 EMPAGLIFLOZIN (addition of note)
Note: Not to be given in combination with a funded GLP-1 agonist.

➔ Tab 10 mg	58.56	30	Jardiance
➔ Tab 25 mg	58.56	30	Jardiance

12 EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE (addition of note)
Note: Not to be given in combination with a funded GLP-1 agonist.

➔ Tab 5 mg with 1,000 mg metformin hydrochloride	58.56	60	Jardiamet
➔ Tab 5 mg with 500 mg metformin hydrochloride	58.56	60	Jardiamet
➔ Tab 12.5 mg with 1,000 mg metformin hydrochloride	58.56	60	Jardiamet
➔ Tab 12.5 mg with 500 mg metformin hydrochloride	58.56	60	Jardiamet

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 September 2021 (continued)

12 GLP-1 Agonists (new TG3, new listing and restriction)

Restricted
Initiation
Any of the following:
1. For continuation use; or
2. Patient has previously had an initial approval for an SGLT-2 inhibitor; or
3. All of the following;
   3.1. Patient has type 2 diabetes; and
   3.2. Any of the following:
      3.2.1. Patient is Māori or any Pacific ethnicity*; or
      3.2.2. Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
      3.2.3. Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
      3.2.4. Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
      3.2.5. Patient has diabetic kidney disease (see note b)*; and
   3.3. Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Note: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.

a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.

b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m^2 in the presence of diabetes, without alternative cause.

12 DULAGLUTIDE (new listing)

Note: Not to be given in combination with a funded SGLT-2 inhibitor.

➔ Inj 1.5 mg per 0.5 ml prefilled pen ..... 115.23 4 Trulicity

13 MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CITRIC ACID WITH MAGNESIUM OXIDE, SODIUM PICOSULFATE (new listing)

Powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet (2) *e.g Prepkit-C*

20 TAURINE (new listing)

➔ Cap 500 mg

22 THYMOL GLYCERIN (delisting)

Compound, BPC ..... 9.15 500 ml PSM

Note – PSM brand to be delisted 1 February 2022.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2021 (continued)

CARDIOVASCULAR SYSTEM

40 QUINAPRIL (addition of PSS)

Tab 5 mg – **5% DV Feb-22 to 2024** (↓ price)	5.97	90	**Arrow-Quinapril 5**
Tab 10 mg – **5% DV Feb-22 to 2024** (↑ price)	5.18	90	**Arrow-Quinapril 10**
Tab 20 mg – **5% DV Feb-22 to 2024** (↑ price)	7.95	90	**Arrow-Quinapril 20**

47 BEZAFIBRATE (↑ price and addition of PSS)

Tab 200 mg – **5% DV Feb-22 to 2024**	19.46	90	**Bezalip**
Tab long-acting 400 mg – **5% DV Feb-22 to 2024**	21.21	30	**Bezalip Retard**

DERMATOLOGICALS

57 HYDROCORTISONE BUTYRATE (↓ price)

Crm 0.1%	4.85	100 g	Locoid Lipocream

57 MOMETASONE FUROATE (addition of PSS)

Crm 0.1% – **5% DV Feb-22 to 2024** (↑ price)	1.95	15 g	**Elocon Alcohol Free**
	3.10	50 g	**Elocon Alcohol Free**
Oint 0.1% – **5% DV Feb-22 to 2024** (↑ price)	1.95	15 g	**Elocon**
(no price change)	2.90	50 g	**Elocon**
Lotn 0.1% – **5% DV Feb-22 to 2024** (↓ price)	4.50	30 ml	**Elocon**

GENITO-URINARY SYSTEM

63 OXYBUTYNIN – Restricted: For continuation only (delisting)

➔ Oral liq 5 mg per 5 ml	60.40	473 ml	Apo-Oxybutynin

Note – Apo-Oxybutynin oral liq 5 mg per 5 ml to be delisted 1 May 2022. This delist is for the Apo-Oxybutynin brand only.

HORMONE PREPARATIONS

67 CABERGOLINE (amended restriction criteria)

➔Tab 0.5 mg	3.75	2	Dostinex
	15.20	8	Dostinex

Restricted
Initiation
Any of the following:
1. Inhibition of lactation; or
2. Patient has ~~pathological~~ hyperprolactinemia; or
3. Patient has acromegaly*.

Note: Indication marked with * is an unapproved indication.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2021 (continued)

INFECTIONS

77 CLARITHROMYCIN (brand change and addition of HSS)

➔ Tab 250 mg – **1% DV Feb-22 to 2024**	8.53	14	**Klacid**
➔ Tab 500 mg – **1% DV Feb-22 to 2024**	14.58	14	**Klacid**

Note – Apo-Clarithromycin tab 250 mg and 500 mg to be delisted 1 February 2022.

89 LOPINAVIR WITH RITONAVIR (brand change and addition of PSS)

➔ Tab 100 mg with ritonavir 25 mg – **5% DV Feb-22 to 2024**	150.00	60	**Lopinavir/Ritonavir Mylan**
➔ Tab 200 mg with ritonavir 50 mg – **5% DV Feb-22 to 2024**	295.00	120	**Lopinavir/Ritonavir Mylan**

Note – Kaletra tab 100 mg with ritonavir 25 mg and tab 200 mg with ritonavir 50 mg to be delisted 1 February 2022.

MUSCULOSKELETAL SYSTEM

104 DICLOFENAC SODIUM (brand change)

Tab long-acting 75 mg	19.60	100	**Voltaren SR**

Note – Apo-Diclo SR tab long-acting 75 mg to be delisted 1 May 2022.

NERVOUS SYSTEM

106 BROMOCRIPTINE (delisting)

➔ Tab 2.5 mg – Restricted: For continuation only

Note – Bromocriptine tab 2.5 mg presentation is to be delisted 1 March 2022.

107 KETAMINE (delisting delayed and ↓ price)

Inj 100 mg per ml, 2 ml ampoule	28.50	5	Ketamine-Baxter

Note – Ketamine-Baxter inj 100 mg per ml, 2 ml ampoule delisting delayed to 1 Janurary 2022.

110 LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE (new listing)

Inj 2% with adrenaline 1:100,000, 1.7 ml dental cartridge

114 CLOMIPRAMINE HYDROCHLORIDE (brand change and addition of HSS)

Tab 10 mg – **1% DV Feb-22 to 2024**	10.17	30	**Clomipramine Teva**
Tab 25 mg – **1% DV Feb-22 to 2024**	11.99	30	**Clomipramine Teva**

Note – Apo-Clomipramine tab 10 mg and 25 mg to be delisted 1 February 2022.

115 CITALOPRAM HYDROBROMIDE (↑ price and addition of PSS)

Tab 20 mg – **5% DV Feb-22 to 2024**	1.91	84	**PSM Citalopram**

116 GABAPENTIN (brand change and addition of HSS)

Note: Gabapentin not to be given in combination with pregabalin

Cap 100 mg – **1% DV Feb-22 to 2024**	6.45	100	**Nupentin**
Cap 300 mg – **1% DV Feb-22 to 2024**	8.45	100	**Nupentin**
Cap 400 mg – **1% DV Feb-22 to 2024**	10.26	100	**Nupentin**

Note – Apo-Gabapentin cap 100 mg, 300 mg and 400 mg are to be delisted 1 February 2022.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2021 (continued)

119 SUMATRIPTAN (brand change and change of HSS)

Tab 50 mg – **1% DV Feb-22 to 2024**	14.41	90	**Sumagran**
Tab 100 mg – **1% DV Feb-22 to 2024**	22.68	90	**Sumagran**

Note – Apo-Sumatriptan tab 50 mg and 100 mg to be delisted 1 February 2022 and HSS to be expired 31 August 2021.

119 DOMPERIDONE (↑ price and addition of PSS)

Tab 10 mg – **5% DV Feb-22 to 2024**	2.85	100	**Pharmacy Health**

128 RIVASTIGMINE (brand change and addition of PSS)

➔ Patch 4.6 mg per 24 hour – **5% DV Feb-22 to 2024**	38.00	30	**Rivastigmine Patch BNM 5**
➔ Patch 9.5 mg per 24 hour – **5% DV Feb-22 to 2024**	38.00	30	**Rivastigmine Patch BNM 10**

Note – Generic Partners patch 4.6 mg per 24 hour and 9.5 mg per 24 hour to be delisted 1 February 2022.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

134 FLUOROURACIL (brand change and addition of PSS)

Inj 50 mg per ml, 20 ml vial – **5% DV Feb-22 to 2024**	10.51	1	**Fluorouracil Accord**
Inj 50 mg per ml, 100 ml vial– **5% DV Feb-22 to 2024**	29.44	1	**Fluorouracil Accord**

Note – Fluorouracil Ebewe inj 50 mg per ml, 20 ml, and 100 ml vial to be delisted from 1 February 2022.

149 OCTREOTIDE (presentation description change, brand change, addition of PSS and amended restriction criteria – new criteria shown only)

➔ Inj **depot** 10 mg **prefilled syringe** ~~vial~~ – **5% DV Mar-22 to 2024**	439.97	1	**Octreotide Depot Teva**
➔ Inj **depot** 20 mg **prefilled syringe** ~~vial~~ – **5% DV Mar-22 to 2024**	647.03	1	**Octreotide Depot Teva**
➔ Inj **depot** 30 mg **prefilled syringe** ~~vial~~ – **5% DV Mar-22 to 2024**	718.55	1	**Octreotide Depot Teva**

Restricted
Initiation – pre-operative acromegaly
Limited to 12 months treatment
All of the following:
1 Patient has acromegaly; and
2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and
3 Patient is scheduled to undergo pituitary surgery in the next six months.
Note – Sandostain LAR inj depot 10 mg, 20 mg and 30 mg prefilled syringe are to be delisted 1 March 2022.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2021 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

208 ICATIBANT (Pharmacode change)
Inj 10 mg per ml, 3 ml prefilled syringe ..... 2,668.00 1 Firazyr
Note – this listing is for Pharmacode 2617560. Pharmacode 2440180 is to be delisted 1 March 2022.

SENSORY ORGANS

220 SODIUM HYALURONATE [HYALURONIC ACID] (presentation change and transfer of HSS)
Inj 18 mg per ml, 0.85 ml syringe – **1% DV Sep-21 to 2022** ... 50.00 1 **Healon GV Pro**
Note – Healon GV inj 14 mg per ml, 0.55 ml syringe to be delisted 1 January 2022 and HSS to be expired 31 August 2021.

221 LATANOPROST (↑ price and addition of PSS)
Eye drops 0.005% – **5% DV Feb-22 to 2024**..... 1.82 2.5 ml **Teva**

223 SODIUM HYALURONATE [HYALURONIC ACID] (delisting of Pharmacode brought forward)
Eye drops 1 mg per ml..... 13.85 10 ml Hylo-Fresh
Note – Hylo-Fresh eye drops 1 mg per ml (Pharmacode 2396238) to be delisted 1 September 2021. This delist has been brought forward from 1 January 2022.

VARIOUS

224 FLUMAZENIL (↓ price and addition of PSS)
Inj 0.1 mg per ml, 5 ml ampoule
– **5% DV Feb-22 to 2024**..... 110.12 10 **Hameln**

Index

Pharmaceuticals and brands

New Zealand
Permit No. 478

Permit

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print)
ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand